117 related articles for article (PubMed ID: 25339217)
1. Clinical response to bevacizumab in schwannomatosis.
Blakeley J; Schreck KC; Evans DG; Korf BR; Zagzag D; Karajannis MA; Bergner AL; Belzberg AJ
Neurology; 2014 Nov; 83(21):1986-7. PubMed ID: 25339217
[No Abstract] [Full Text] [Related]
2. Schwannomatosis presenting with large subcutaneous and retroperitoneal tumours.
Yoshizawa M; Sugita K; Haruyama S; Yoshiki R; Hino R; Bito T; Nakamura M; Tokura Y
Clin Exp Dermatol; 2011 Jul; 36(5):555-7. PubMed ID: 21392082
[No Abstract] [Full Text] [Related]
3. Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment.
Morris KA; Parry A; Pretorius PM
Br J Radiol; 2016 Sep; 89(1065):20160110. PubMed ID: 27452262
[TBL] [Abstract][Full Text] [Related]
4. Schwannomatosis on a single foot: a case report.
Min HJ; Kim KC; Jun SH; Lee YG
Foot Ankle Spec; 2015 Jun; 8(3):226-9. PubMed ID: 25547315
[TBL] [Abstract][Full Text] [Related]
5. Schwannomatosis: the overlooked neurofibromatosis?
Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
[TBL] [Abstract][Full Text] [Related]
6. Intralesional bevacizumab for cutaneous capillary haemangioma associated with pregnancy.
Steeples LR; Bonshek R; Morgan L
Clin Exp Ophthalmol; 2013; 41(4):413-4. PubMed ID: 22957786
[No Abstract] [Full Text] [Related]
7. Schwannomatosis/neurofibromatosis type 2 associated multiple schwannomas visualized on FDG-PET/CT.
Beylergil V; Haque S; Carver A; Bilsky MH; Carrasquillo JA
Rev Esp Med Nucl Imagen Mol; 2013; 32(4):275-6. PubMed ID: 23582492
[No Abstract] [Full Text] [Related]
8. Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.
Strowd RE
Curr Treat Options Oncol; 2020 Aug; 21(10):81. PubMed ID: 32767156
[TBL] [Abstract][Full Text] [Related]
9. Recurrent knee pain in an athletic adult: multiple schwannomas secondary to schwannomatosis: a case report.
Maceroli M; Uglialoro AD; Beebe KS; Benevenia J
Am J Orthop (Belle Mead NJ); 2010 Nov; 39(11):E119-22. PubMed ID: 21623424
[TBL] [Abstract][Full Text] [Related]
10. Unresectable angiosarcoma treated with bevacizumab and paclitaxel.
Nespereira-Jato MV; Peña-Panabad C; Quindós-Varela M; García-Silva J
Actas Dermosifiliogr; 2014 Jun; 105(5):520-2. PubMed ID: 24144236
[No Abstract] [Full Text] [Related]
11. Whole-body imaging in schwannomatosis.
Chhabra A; Blakely J
Neurology; 2011 Jun; 76(23):2035. PubMed ID: 21646633
[No Abstract] [Full Text] [Related]
12. Schwannomatosis affecting all three major nerves in the same upper extremity.
Saito S; Suzuki Y
J Hand Surg Eur Vol; 2010 Sep; 35(7):592-4. PubMed ID: 20719892
[No Abstract] [Full Text] [Related]
13. Neurofibromas in LZTR1 schwannomatosis.
Groen JL; Moghadasi S; Spruijt L; Korpershoek E; van Ierland Y; van Wezel JT; van Duinen S; Malessy MJA; Lesnik Oberstein SAJ
Clin Genet; 2022 May; 101(5-6):571-572. PubMed ID: 35178712
[No Abstract] [Full Text] [Related]
14. Neurofibromatosis type 2 (NF 2) or schwannomatosis?--Case report study and diagnostic criteria.
Radek M; Tomasik B; Wojdyn M; Snopkowska-Wiaderna D; Błaszczyk M; Radek A
Neurol Neurochir Pol; 2016; 50(3):219-25. PubMed ID: 27154453
[TBL] [Abstract][Full Text] [Related]
15. Sporadic Schwannomatosis: A Systematic Review Following the 2005 Consensus Statement.
Chick G; Victor J; Poujade T; Hollevoet N
J Neurol Surg A Cent Eur Neurosurg; 2018 Sep; 79(5):408-415. PubMed ID: 29902824
[TBL] [Abstract][Full Text] [Related]
16. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
17. Segmental Schwannomatosis of the Spine: Report of a Rare Case and Brief Review of Literature.
Baruah RK; Bora S; Haque R
Ortop Traumatol Rehabil; 2016; 18(1):73-8. PubMed ID: 27053311
[TBL] [Abstract][Full Text] [Related]
18. Proliferative retinopathy in Duchenne muscular dystrophy and its response to bevacizumab.
Fagan XJ; Levy J; Al-Qureshi S; Harper CA
Clin Exp Ophthalmol; 2012 Dec; 40(9):906-7. PubMed ID: 22594924
[No Abstract] [Full Text] [Related]
19. Creation of an international registry to support discovery in schwannomatosis.
Ostrow KL; Bergner AL; Blakeley J; Evans DG; Ferner R; Friedman JM; Harris GJ; Jordan JT; Korf B; Langmead S; Leschziner G; Mautner V; Merker VL; Papi L; Plotkin SR; Slopis JM; Smith MJ; Stemmer-Rachamimov A; Yohay K; Belzberg AJ
Am J Med Genet A; 2017 Feb; 173(2):407-413. PubMed ID: 27759912
[TBL] [Abstract][Full Text] [Related]
20. How should we use bevacizumab in patients with non-small cell lung cancer?
Kim YH; Mishima M
J Thorac Oncol; 2011 Dec; 6(12):2145-6. PubMed ID: 22088996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
